Monitoring drug action on signalling pathways and networks
  • SignallingScout™ enables the comprehensive profiling of dynamic phosphorylation events in up to 100s of samples
  • SignallingScout™ can be used to reveal cellular modes of action for small molecule kinase inhibitors and to identify pharmacodynamic signatures for therapeutic kinase inhibition (i.e. signalling sign-posts)
  • The technology can also support the selection of lead compounds or pre-clinical candidates to maximize on- and reduce off-target activity in cellular conditions, either as single agents or in combination with other drugs
  • Monitoring phosphoproteome regulation in different biological models can reveal factors underlying differential biological activity of lead compounds or preclinical candidates


Further reading

Cutillas, P.R. (2015) Role of phosphoproteomics in the development of personalized cancer therapies, Proteomics Clin Appl 9(3-4):383-95. [Link]

Schirle, M., Bantscheff, M., and Kuster, B. (2012). Mass Spectrometry-based Proteomics in Preclinical Drug Discovery, Chem Biol 19(1):72-84. [Link]


Schematic representation of cellular signalling pathways
SignallingScout™ enables the comprehensive analysis of signal pathway and network activities in different samples or conditions (e.g. in stimulated or inhibitor treated cells).